418 results about "Ionic Channels" patented technology

Single-channel thin film devices and methods for using the same are provided. The subject devices comprise cis and trans chambers connected by an electrical communication means. At the cis end of the electrical communication means is a horizontal conical aperture sealed with a thin film that includes a single nanopore or channel. The devices further include a means for applying an electric field between the cis and trans chambers. The subject devices find use in applications in which the ionic current through a nanopore or channel is monitored where such applications include the characterization of naturally occurring ion channels, the characterization of polymeric compounds, and the like.

A field effect transistor device includes: a reservoir bifurcated by a membrane of three layers: two electrically insulating layers; and an electrically conductive gate between the two insulating layers. The gate has a surface charge polarity different from at least one of the insulating layers. A nanochannel runs through the membrane, connecting both parts of the reservoir. The device further includes: an ionic solution filling the reservoir and the nanochannel; a drain electrode; a source electrode; and voltages applied to the electrodes (a voltage between the source and drain electrodes and a voltage on the gate) for turning on an ionic current through the ionic channel wherein the voltage on the gate gates the transportation of ions through the ionic channel.

The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia.

The present invention includes a group of chemical compounds useful as modulators of calcium ion (Ca2+) channels, especially for T-type, N-Type and L-type channels. The present invention also includes pharmaceutical compositions comprising these calcium ion channel modulating agents and methods of using these calcium ion channel modulating agents for the treatment diseases and conditions associated with the calcium ion channels.

A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment / modulation of pain and processes for generating and preparing said antibodies.

One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.

A multi-channel apparatus through which saline water flows continuously contains two separate series of channelways defined by porous membranes. The membranes have pore sizes such that a wide variety of dissolved ions can pass through them. Electrodes or capacitors suitable for attracting dissolved ions are provided within each of the channels in one of the sets of water channelways (“the concentrate channelways”). Ions are concentrated within the series of channelways in which the electrodes or capacitors are provided by applying electrically attractive force in order to capture, concentrate, and remove the dissolved ions from the other series of deionized channelways (“the deionization channelways”). Ions are captured from both sets of channelways and concentrated in the concentrate channels. The concentrate and deionized water streams flow continuously through their respective series of channelways and are removed from the apparatus separately to keep the concentrate and deionized water from mixing. Two streams of water exit from the apparatus. None of the deionized product water is used for flushing ion concentrates.

The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Systems for positioning and / or analyzing samples such as cells, vesicles, cellular organelles, and fragments, derivatives, and mixtures thereof, for electrical and / or optical analysis, especially relating to the presence and / or activity of ion channels.

A method to prepare viruses lacking ion channel activity is provided.

A portable Static Electro Magnetic Field (SEMF) generating device and method for the therapeutic treatment of inflammatory and painful disorders of the human limbs including fingers, hands, wrists, forearms, elbows, toes, feet and ankles preferably includes a wearable, portable battery powered solenoid or coil. The coil is configured to focus a substantially time invariant magnetic flux field onto a selected part of the body. The SEMF generating device's coil, when energized, works by slightly changing the charges associated with voltage-dependant ion channels in the cell membranes of the human body, thereby stabilizing abnormal fluid transport into the cells through aquaporin channels and the sodium ions relating to them, treating inflammation and altering the flow of calcium, chloride and potassium ions through their respective neuronal ion channels and treating pain.

Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Particular aspects of the present invention provide compositions and methods suitable for modulation of at least one of cellular membrane potential and cellular membrane conductivity. Additional aspects provide compositions and methods suitable for modulating intracellular signal transduction, including modulation of at least one of membrane structure, membrane potential or membrane conductivity, membrane proteins or receptors, ion channels, and calcium dependant cellular messaging systems, comprising use of the inventive electrokinetically altered solutions to impart electrochemical and / or conformational changes in membranous structures (e.g., membrane proteins, receptors and / or other components) including G-protein coupled receptors (GPCRs), G-proteins, and / or intracellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).

The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

The invention features an optically-controlled biological device that includes a biological component comprising a non-excitable cell expressing a light-gated ion channel protein and capable of forming gap junction channels with a target cell, and an optical stimulation unit.

The present invention relates to compounds useful as inhibitors of voltage-gated ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

The invention discloses a preparation method and application of a transparent titanium dioxide nanotube film. Firstly, a titanium sheet is subjected to a primary anodic oxidation, ultrasonic cleaning and secondary anodic oxidation to form a titanium dioxide nanotube array; the titanium dioxide nanotube array is subjected to low temperature annealing; the titanium dioxide nanotube array is quickly peeled from a substrate titanium through high-voltage anodization to obtain the titanium dioxide nanotube self-supporting film with a regular shape and two transparent ends. The preparation method is simple, low in price, environment-friendly and beneficial for large-scale application. The low temperature annealing treatment can effectively protect the strength and the thickness of the film and has very important effect on the film application. The preparation method and the application of the transparent titanium dioxide nanotube film utilize intelligent response functions of ion channels in titanium dioxide nanotube film simulated organisms to built artificial ion channels with photoresponse, and overcome the instability of organic materials in the traditional artificial ion channels and the limitation of biological material application.

One aspect of the present invention relates to heterocyclic compounds comprising a sulfonamide moiety. A second aspect of the present invention relates to the use of the heterocyclic compounds comprising a sulfonamide moiety to treat diseases, afflictions or maladies caused at least in part by abnormal activity of one or more GPCRs or ligand-gated ion channels. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds comprising a sulfonamide moiety, and the screening of those libraries for biological activity, e.g., in animal models of psychosis.

A compound of formula (I)wherein A, R1, R3, and R24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment of arrhythmia, maintaining normal sinus rhythm, IKur-associated disorders, and other disorders mediated by ion channel function.

The invention discloses a long-branched-chain polysulfone anionic membrane and a preparation method thereof. The structure of the membrane material is disclosed in the specification. The preparation method comprises the following steps: polysulfone acylation, carbonyl reduction, quaternization, film formation, alkalification and the like. Compared with the traditional anion-exchange membrane sequentially subjected to quaternization and functionalization, the polysulfone anion-exchange membrane contains the long branched chain on the side chain, so that the hydrophilic group is far away from the hydrophobic polymer main chain, thereby enhancing the phase separation driving force in the film formation process, improving the connectivity of the ion channels in the membrane and further enhancing the hydroxide ion conductivity of the membrane. The long alkyl side chain can obviously reduce the degree of swelling of the quaternary ammonium salt membrane and reduce the nucleophilic attack of water or OH-. The long-branched-chain polysulfone anionic membrane can obtain higher ion conductivity on the premise of relatively lower water absorptivity, thereby solving the contradiction in the anionic membrane for a long time.

A computer readable medium holding data of a molecular model of a ligand-gated ion channel receptor and / or a computer system for modeling said receptor are provided by the instant invention. The molecular model can be used to design novel compounds having activity as non-competitive inhibitors of the ion channel. A preferred embodiment of the invention relates to nicotinic acetylcholine receptors. Compounds having activity as non-competitive inhibitors of ligand-gated ion channel receptors and methods for inhibiting the receptor and treating diseases or disorders mediated by function of the receptor are also disclosed.

A method for measuring membrane potential using dielectric spectroscopy is described. A new theoretical model allows for the determination of membrane potential from low-frequency impedance measurements to provide a non-evasive method which is both rapid and inexpensive.

The invention discloses new application of 6-gingerol. The 6-gingerol is used for respectively regulating M8 and V1 subtype transient receptor potential ion channels (short for TRPM8 and TRPV1) of mammals including humans and can be also used for preparing medicaments for treating related diseases, such as cryalgesia allergy, the parkinsonism, painful bladder syndrome, chronic obstructive pulmonary diseases, and the like as well as tumors of skin, the prostate gland, the mammary gland, the lung, the colon, and the like, participated by the ion channels. The action intensity of the 6-gingerol is higher than that of capsaicin.

The invention relates to a specific probe substrate composition of cytochrome P450 (CYP450) enzyme and an application of the specific probe substrate composition in subtype enzyme activity detection of the cytochrome P450 enzyme. The composition comprises at least two of phenacetin, coumarin, amfebutamone, dextromethorphan, diclofenac and testosterone. The characteristics of multi-ion channels can be simultaneously detected by the specific probe substrate composition and a liquid chromatography-mass spectrometry technology, and the inhibition conditions of six CYP450 enzymes are determined simultaneously, so that the experiment flux efficiency is greatly improved, and the experiment cost is reduced.

The present invention provides methods to manipulate differentiation of a neuroblastoma cell line (IMR-32) such that predominant Nav expression is either Nav1.3 in IMR-32 cells exposed to retinoic acid or Nav1.7 in cells grown under non-differentiating conditions. The cells of the present invention are useful for the discovery of new compounds that modulate the function of either Nav1.3 and / or Nav1.7.

The invention discloses an isoquinoline compound or salt thereof shown as a formula I, wherein R1 and R2 are H, -OCH3 and -OCH2Ph or -NHSO2CH3 independently or R1 and R2 are connected into -OCH2O-; R3 is -NO2, -NH2 or -NHSO2CH3; and R4, R5, R6 and R7 are independently H, -OCH3, -NO2, -NH2 or -NHSO2CH3. The invention also discloses a preparation method of the compound, the medicinal composition containing the compound, and application of the compound in preparing medicaments for treating anti-arrhythmia. The isoquinoline compound or salt thereof has the effect of potassium ion channel blocker, and shows effective activity of prolonging effective refractory period and better heart selectivity, so the isoquinoline compound or salt thereof has better anti-arrhythmia activity.

Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia.

The invention discloses a midget anti drug-tolerance staphylococcus aureus polypeptide comprised of passage structure domain to form ion channel colicine and staphylococcus aureu pheromone, as well as opposite coded nucleotide sequence and recombination plasmid contained said sequence. Wherein, the plupeptide can not induce bacteria to generate trsditional drug-tolerance by the mechnism that it forms directly ion channel on cell film of target cell to kill bacteria. This invention has more single antimicrobial spectrum without effect to Gram-negative bacteria of escherichia coli, shows at least 500 times effect to pheneazonecillin, and can be used as synergist to beta-lactam antibiotics.

The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

This invention is directed to PEGlyated derivatives, drug conjugates and isotopic derivatives of certain ion channel modulating compounds. Pharmaceutical compositions and methods of use of also disclosed